News :: Kazia Therapeutics (KZIA)

Jun 8, 2023 7:00 am EDT KAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE 2 & 3 GLIOMA

May 25, 2023 7:01 am EDT KAZIA CEO, DR. JOHN FRIEND TO PARTICIPATE IN WHITE HOUSE CANCER MOONSHOT

Apr 14, 2023 7:01 am EDT KAZIA REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT

Apr 4, 2023 7:00 am EDT KAZIA PRESENTS NEW DATA FOR PAXALISIB AND EVT801 AT AACR ANNUAL MEETING

Jan 18, 2023 11:50 am EST Kazia Therapeutics CEO talks $4.5 million capital raise

Jan 16, 2023 7:01 am EST KAZIA RAISES A$4.5 MILLION TO PROGRESS R&D PROGRAMS

Dec 15, 2022 7:01 am EST KAZIA LAUNCHES PRECLINICAL COLLABORATION WITH QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE AND ANNOUNCES PATENT FILING

Dec 12, 2022 7:01 am EST KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION

Dec 6, 2022 11:45 am EST Kazia Therapeutics talks positive pre-clinical data for EVT801